The termination removes a major source of potential future revenue and validation for TScan's platform, increasing reliance on its internal pipeline. Traders should watch for the company's next update on cash runway and pipeline progress, as the loss of this partnership may accelerate cash burn concerns.
Price Chart
Executive Summary
TScan Therapeutics disclosed that Amgen terminated their Research Collaboration and License Agreement for Crohn's disease, effective November 10, 2026. This ends a partnership that included a $30M upfront payment (received in 2023) and over $500M in potential milestones, with no termination penalty owed by TScan. The loss of future milestone and royalty revenue is a material negative for the company, which has a $50M market cap and no approved products.
Key Facts
- Amgen terminated the Research Collaboration and License Agreement with TScan Therapeutics on August 12, 2026, effective November 10, 2026.
- No early termination penalty is payable by TScan in connection with the termination.
- The agreement provided for a non-refundable upfront payment of $30.0 million (received in 2023), success-based milestone payments of over $500 million in aggregate, and tiered single-digit royalty payments.
- TScan is obligated to wind down its activities under the research plan; licenses granted under the agreement will terminate.
- TScan does not expect to receive future milestone or royalty payments unless Amgen continues to exploit product candidates.
Financial Impact
Loss of potential future milestone payments exceeding $500 million and tiered single-digit royalties on net sales; no termination fee received.
Risk Factors
- Loss of a major partnership with Amgen removes a key value driver and potential revenue stream.
- TScan's reliance on its internal pipeline increases, with no guarantee of clinical or regulatory success.
- The company's $50M market cap and pre-revenue status make it highly sensitive to this setback.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-355664 |
| Document: 0001193125-26-355664-index-headers.html | 0001193125-26-355664 |
| Document: 0001193125-26-355664-index.html | 0001193125-26-355664 |
| Document: 0001193125-26-355664.txt | 0001193125-26-355664 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $0.3204 $0.3119 | ▼ −2.65% | ▼ −2.43% | $0.3242 (+1.19%) |
Sep 2, 2026 4w ago | 8-K | $0.3810 $0.3179 | ▲ +16.56% | ▲ +15.60% | $0.3242 (+14.91%) |
Aug 18, 2026 6w ago | 8-K | $0.7500 $0.7774 | ▼ −3.65% | ▼ −4.04% | $0.3242 (+56.77%) |
Aug 12, 2026 7w ago | 8-K | $0.7730 $0.7500 | ▲ +2.98% | ▲ +2.53% | $0.3242 (+58.06%) |
Aug 12, 2026 7w ago | Press Release | $0.7730 $0.7500 | ▲ +2.98% | ▲ +2.53% | $0.3242 (+58.06%) |
Jun 22, 2026 14w ago | 8-K | $0.8651 $0.9775 | ▲ +12.99% | ▲ +13.45% | $0.3242 (−62.52%) |
Jun 22, 2026 14w ago | Press Release | $0.8651 $0.9688 | ▲ +11.99% | ▲ +14.06% | $0.3242 (−62.52%) |
May 6, 2026 21w ago | 8-K | $1.25 $1.15 | ▼ −8.00% | ▼ −9.13% | $0.3242 (−74.06%) |
Apr 2, 2026 26w ago | 8-K | $1.01 $1.05 | ▲ +3.96% | ▲ +0.34% | $0.3242 (−67.90%) |
Mar 4, 2026 30w ago | Press Release | $1.08 $1.15 | ▲ +6.48% | ▲ +7.81% | $0.3242 (−69.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access